Seeking Alpha

Leonard Yaffe's  Instablog

Leonard Yaffe
Send Message
I am an MD by background who runs a healthcare hedge fund. I worked as a sell-side medical analyst for 20 years, covering pharmaceuticals, medical devices, PBMs and drug distributors.
  • Hepatitis C Update 0 comments
    Nov 11, 2013 11:05 AM | about stocks: OSUR, GILD, JNJ

    Last Friday, I attended the California Forum on Hepatitis C Screening and Treatment. In attendance were clinicians and, importantly, policy makers. I make the latter distinction because policy decisions will greatly influence Hepatitis C screening and treatment. My conclusions are as follows:

    1. Hepatitis C screening in the 1945-'65 birth year cohort is very supported, including on an objective $/QALY, as it is cost-effective on this basis at $36k, which compares favorably with screening for colorectal cancer, breast cancer and cervical cancer. Furthermore, the USPTF's Grade B designation will facilitate screening as well. This should be a positive for OSUR.

    2. Screening of the 1945-65 cohort could result in an incremental 800k cases of Hepatitis C being identified.

    3. It is possible that Medicare coverage for HCV testing will occur in 2014.

    4. The AASLD and IDSA have formed a joint committee to make recommendations for Hepatitis C treatment. It is likely that one recommendation will be to support the use of sofosbuvir (NASDAQ:GILD) in combination with simeprevir (NYSE:JNJ) in Genotype 1 patients, off label, based on the COSMOS study. I view this as potentially very positive for both GILD and JNJ.

    5. The pharmacoeconomic data in support of treating Hepatitis C are quite compelling.

    6. I commend Kaiser of California for the Hepatitis C program they have put in place.

    Disclosure: I am long OSUR, GILD, JNJ.

    Themes: Hepatitis C Stocks: OSUR, GILD, JNJ
Back To Leonard Yaffe's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


  • $GILD Gilead Anthem deal, if no patient exclusions (ie fibrosis stage), is another example of trading volume for price. Win-win. BUY GILD
    Jan 8, 2015
  • Is There A New Reality To The Drug Industry?
    Dec 23, 2014
  • Update: News On Gilead From The California Technology Assessment Forum $GILD
    Dec 19, 2014
More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.